Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells. [Read more…]
Vitti Labs Announces FDA Approval of IND Application for Phase II Trial of Combination MSC and Exosome Treatment of COVID-19
LIBERTY, Mo., Oct. 26, 2021 — Vitti Labs (www.vittilabs.com), an AATB Accredited Tissue Bank focused on Life Science Research, Development and Manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to conduct Phase II Clinical Trials using a combination of Umbilical Cord Mesenchymal Stem Cell and Umbilical Cord Mesenchymal Stem Cell Exosomes for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with the Novel Corona Virus (COVID-19). This marks the very first time the FDA has approved an IND that uses both of these components together and so first of its kind therapy. [Read more…]
Therapeutic Solutions Utilizes MSC Exosomes to Suppress Inflammatory Pathologies
Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production
Patent Filed on Potential Solution to Cause of Major Inflammatory Pathologies
ELK CITY, Idaho, Oct. 4, 2021 — Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced laboratory data demonstrating that exosomes produced by JadiCells™, the Company’s Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps. [Read more…]
EV Biologics Signs LOI with Lonza Cell & Gene Therapy
NASHVILLE, TN, July 22, 2021 — EV Biologics (OTC PINK:YECO) announced that it has signed a Letter of Intent (LOI) with Lonza Cell & Gene Therapy for Process Development and Gap Analysis for biomanufacturing of a novel therapeutic composition, comprising extracellular vesicles (EVs) and particles, as well as other secreted factors derived from selected stem/progenitor cells, such as mesenchymal stromal cells (MSCs). [Read more…]
Demand for Exosome Technologies Drives Billion Dollar Price Tags
Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, with virtually all living cells utilize exosome-mediated communication. Today, exosomes are being explored across a diverse range of therapeutic and diagnostic applications, with particular attention being given by the pharmaceutical industry to drug-loaded exosomes. [Read more…]
